{"id":10339,"date":"2025-12-03T14:30:10","date_gmt":"2025-12-03T11:30:10","guid":{"rendered":"https:\/\/www.ortaakarsu.net\/?p=10339"},"modified":"2025-12-03T14:30:10","modified_gmt":"2025-12-03T11:30:10","slug":"semaglutid-nedir-glp-1-reseptor-agonisti-ile-kilo-verme-ve-tip-2-diyabet-tedavisi","status":"publish","type":"post","link":"https:\/\/www.ortaakarsu.net\/?p=10339","title":{"rendered":"Semaglutid Nedir? GLP\u20111 Resept\u00f6r Agonisti ile Kilo Verme ve Tip 2 Diyabet Tedavisi"},"content":{"rendered":"<h2>GLP\u20111 Resept\u00f6r Agonisti Semaglutid Nedir?<\/h2>\n<p>\nSemaglutid, <strong>GLP\u20111 (glukagon benzeri peptit\u20111) resept\u00f6r agonisti<\/strong> s\u0131n\u0131f\u0131nda yer alan, protein\u2011peptit yap\u0131l\u0131 bir ila\u00e7t\u0131r. \u0130nsan GLP\u20111 hormonuna y\u00fcksek benzerlik g\u00f6steren bu peptit, birka\u00e7 ak\u0131ll\u0131 kimyasal modifikasyonla v\u00fccutta daha uzun s\u00fcre kalacak \u015fekilde tasarlanm\u0131\u015ft\u0131r. B\u00f6ylece g\u00fcnde birden \u00e7ok doz yerine <strong>haftada tek enjeksiyon<\/strong>la etkili olabilmektedir.\n<\/p>\n<p><img decoding=\"async\" width=\"1024\" height=\"1024\" src=\"https:\/\/www.ortaakarsu.net\/wp-content\/uploads\/glp-1-reseptor-agonisti-semaglutid-obezite-ve-tip-2-diyabet-tedavisinde-protein-peptit-yapili-ilaclarin-yukselisi-detail-content.png\" class=\"aligncenter\" alt=\"\" \/><\/p>\n<\/p>\n<p>\nBa\u015flang\u0131\u00e7ta <strong>tip 2 diyabet<\/strong> tedavisi i\u00e7in geli\u015ftirilen semaglutid, zamanla <strong>klinik \u00e7al\u0131\u015fmalarda belirgin kilo kayb\u0131<\/strong> sa\u011flamas\u0131yla obezite alan\u0131nda da \u00e7\u0131\u011f\u0131r a\u00e7an bir tedavi haline gelmi\u015ftir (doi:10.1056\/NEJMoa1607141; doi:10.1056\/NEJMoa2032183). Bug\u00fcn hem diyabet kontrol\u00fc hem de kilo y\u00f6netimi i\u00e7in en \u00e7ok konu\u015fulan protein\u2011peptit yap\u0131l\u0131 ila\u00e7lardan biridir.\n<\/p>\n<h2>Semaglutid Nas\u0131l \u00c7al\u0131\u015f\u0131r? Mekanizman\u0131n Arkas\u0131ndaki Bilim<\/h2>\n<p>\nSemaglutid, pankreastaki GLP\u20111 resept\u00f6rlerini aktive ederek <strong>\u00e7ok hedefli bir metabolik yan\u0131t<\/strong> olu\u015fturur:\n<\/p>\n<ul>\n<li><strong>\u0130ns\u00fclin sal\u0131n\u0131m\u0131n\u0131 art\u0131r\u0131r:<\/strong> Kan \u015fekeri y\u00fckseldi\u011finde pankreas\u0131n daha fazla ins\u00fclin salg\u0131lamas\u0131n\u0131 destekler.<\/li>\n<li><strong>Glukagonu bask\u0131lar:<\/strong> Karaci\u011ferin gereksiz glukoz \u00fcretimini azalt\u0131r.<\/li>\n<li><strong>Mide bo\u015falmas\u0131n\u0131 yava\u015flat\u0131r:<\/strong> Tokluk hissini uzat\u0131r, ani a\u00e7l\u0131k ataklar\u0131n\u0131 hafifletir.<\/li>\n<li><strong>Beyindeki i\u015ftah merkezini etkiler:<\/strong> \u00d6zellikle hipotalamusta i\u015ftah\u0131 azaltan sinyalleri g\u00fc\u00e7lendirir.<\/li>\n<\/ul>\n<p>\nBu \u00e7ok katmanl\u0131 etki, hem <strong>HbA1c d\u00fc\u015f\u00fc\u015f\u00fc<\/strong> hem de <strong>anlaml\u0131 kilo kayb\u0131<\/strong> ile sonu\u00e7lan\u0131r. \u00d6rne\u011fin SUSTAIN \u00e7al\u0131\u015fmalar\u0131nda semaglutid, di\u011fer GLP\u20111 agonistlerine ve baz\u0131 oral antidiyabetiklere k\u0131yasla daha g\u00fc\u00e7l\u00fc glisemik kontrol ve kilo kayb\u0131 sa\u011flam\u0131\u015ft\u0131r (doi:10.1016\/S0140-6736(17)31412-6).\n<\/p>\n<h2>Obezite Tedavisinde Semaglutid: Kilo Kayb\u0131nda Yeni Standart m\u0131?<\/h2>\n<p>\nObezite tedavisinde kullan\u0131lan semaglutid form\u00fclasyonlar\u0131, diyabet dozlar\u0131ndan genellikle daha y\u00fcksektir. STEP \u00e7al\u0131\u015fmalar\u0131, haftal\u0131k semaglutid enjeksiyonunun, ya\u015fam tarz\u0131 de\u011fi\u015fiklikleriyle birlikte kullan\u0131ld\u0131\u011f\u0131nda <strong>ba\u015flang\u0131\u00e7 v\u00fccut a\u011f\u0131rl\u0131\u011f\u0131n\u0131n %10\u201315\u2019ine varan kilo kayb\u0131<\/strong> sa\u011flayabildi\u011fini g\u00f6stermi\u015ftir (doi:10.1056\/NEJMoa2032183; doi:10.1038\/s41591-021-01398-3).\n<\/p>\n<p>\nBu d\u00fczeyde bir kilo kayb\u0131, yaln\u0131zca estetik bir sonu\u00e7 de\u011fildir:\n<\/p>\n<ul>\n<li>Tip 2 diyabet geli\u015fme riskini azaltabilir.<\/li>\n<li>Kan bas\u0131nc\u0131n\u0131 ve kan ya\u011flar\u0131n\u0131 iyile\u015ftirebilir.<\/li>\n<li>Uyku apnesi, karaci\u011fer ya\u011flanmas\u0131 ve eklem a\u011fr\u0131lar\u0131 gibi obeziteye ba\u011fl\u0131 sorunlar\u0131 hafifletebilir.<\/li>\n<\/ul>\n<p>\nBu nedenle semaglutid, <strong>\u201czay\u0131flama i\u011fnesi\u201d<\/strong> olarak pop\u00fclerle\u015fse de, asl\u0131nda <strong>metabolik hastal\u0131k y\u00fck\u00fcn\u00fc azaltmaya y\u00f6nelik, ciddi klinik verilerle desteklenen<\/strong> bir protein\u2011peptit tedavisidir.\n<\/p>\n<h2>Tip 2 Diyabette Semaglutid: Sadece \u015eeker Kontrol\u00fc De\u011fil<\/h2>\n<p>\nSemaglutid, tip 2 diyabet hastalar\u0131nda:\n<\/p>\n<ul>\n<li><strong>HbA1c de\u011ferlerinde anlaml\u0131 d\u00fc\u015f\u00fc\u015f<\/strong> sa\u011flar.<\/li>\n<li><strong>Hipoglisemi riskini<\/strong> klasik ins\u00fclin tedavilerine g\u00f6re daha d\u00fc\u015f\u00fck tutar.<\/li>\n<li>Ek olarak <strong>kilo kayb\u0131<\/strong> sa\u011flayarak ins\u00fclin direncini de azalt\u0131r.<\/li>\n<\/ul>\n<p>\nBaz\u0131 uzun d\u00f6nem \u00e7al\u0131\u015fmalar, semaglutidin <strong>kardiyovask\u00fcler olay riskini azaltabilece\u011fine<\/strong> i\u015faret etmektedir (doi:10.1056\/NEJMoa1607141). Yani bu ila\u00e7, sadece kan \u015fekerini de\u011fil, <strong>kalp\u2011damar sa\u011fl\u0131\u011f\u0131n\u0131 da<\/strong> hedef alan b\u00fct\u00fcnc\u00fcl bir yakla\u015f\u0131m sunar.\n<\/p>\n<h2>Protein\u2011Peptit Yap\u0131l\u0131 \u0130la\u00e7lar\u0131n Y\u00fckseli\u015fi: Neden K\u00fc\u00e7\u00fck Molek\u00fcllerin \u00d6n\u00fcne Ge\u00e7iyor?<\/h2>\n<p>\nKlasik <strong>k\u00fc\u00e7\u00fck molek\u00fcl ila\u00e7lar<\/strong> (\u00f6rne\u011fin metformin, s\u00fclfonil\u00fcreler) a\u011f\u0131zdan kolayca al\u0131nabilmeleri ve ucuz olmalar\u0131yla avantajl\u0131d\u0131r. Ancak hedef se\u00e7icili\u011fi s\u0131n\u0131rl\u0131 olabilir ve yan etki profilleri daha geni\u015f olabilir. Semaglutid gibi <strong>protein\u2011peptit yap\u0131l\u0131 ila\u00e7lar<\/strong> ise:\n<\/p>\n<ul>\n<li>Hedef resept\u00f6re <strong>daha y\u00fcksek \u00f6zg\u00fcll\u00fck<\/strong> g\u00f6sterir.<\/li>\n<li>Fizyolojik hormonlar\u0131 taklit ederek <strong>do\u011fala daha yak\u0131n bir etki<\/strong> olu\u015fturur.<\/li>\n<li>Yeni kimyasal modifikasyonlarla <strong>yar\u0131 \u00f6m\u00fcrleri uzat\u0131labilir<\/strong>, haftal\u0131k veya daha seyrek dozlanabilir.<\/li>\n<\/ul>\n<p>\nBu nedenle semaglutid, <strong>\u201cpeptit bazl\u0131 metabolik ila\u00e7lar\u201d<\/strong> \u00e7a\u011f\u0131n\u0131n sembol molek\u00fcllerinden biri haline gelmi\u015ftir ve gelecekte GIP, amilin, glukagon agonistleriyle kombine peptitlerin \u00f6n\u00fcn\u00fc a\u00e7maktad\u0131r (doi:10.1038\/s41573-021-00144-4).\n<\/p>\n<h2>Semaglutid G\u00fcvenli mi? Yan Etkiler ve Dikkat Edilmesi Gerekenler<\/h2>\n<p>\nSemaglutid genellikle iyi tolere edilir, ancak \u00f6zellikle tedavinin ba\u015f\u0131nda:\n<\/p>\n<ul>\n<li><strong>Bulant\u0131, kusma<\/strong><\/li>\n<li><strong>\u0130shal veya kab\u0131zl\u0131k<\/strong><\/li>\n<li>Mide dolgunlu\u011fu, i\u015ftah azalmas\u0131<\/li>\n<\/ul>\n<p>\ngibi <strong>mide\u2011ba\u011f\u0131rsak yan etkileri<\/strong> s\u0131k g\u00f6r\u00fclebilir. Dozun yava\u015f art\u0131r\u0131lmas\u0131yla bu etkiler genellikle hafifler (doi:10.1111\/dom.13494). Nadiren pankreatit, safra kesesi sorunlar\u0131 veya ciddi alerjik reaksiyonlar rapor edilmi\u015ftir.\n<\/p>\n<p>\n\u00d6nemli nokta: Semaglutid, <strong>kilo vermek isteyen herkesin \u201cdeneyebilece\u011fi\u201d bir kozmetik \u00fcr\u00fcn de\u011fil<\/strong>, mutlaka hekim g\u00f6zetiminde, uygun endikasyon ve dozla kullan\u0131lmas\u0131 gereken <strong>re\u00e7eteli bir protein\u2011peptit ila\u00e7t\u0131r<\/strong>.\n<\/p>\n<h2>Sonu\u00e7: Semaglutid, Metabolik Hastal\u0131klarda Yeni Bir D\u00f6nem mi Ba\u015flat\u0131yor?<\/h2>\n<p>\nSemaglutid, obezite ve tip 2 diyabet tedavisinde:\n<\/p>\n<ul>\n<li>G\u00fc\u00e7l\u00fc kilo kayb\u0131<\/li>\n<li>\u0130yi glisemik kontrol<\/li>\n<li>Muhtemel kardiyovask\u00fcler faydalar<\/li>\n<\/ul>\n<p>\nsunarak, protein\u2011peptit yap\u0131l\u0131 ila\u00e7lar\u0131n k\u00fc\u00e7\u00fck molek\u00fcl tedavilere g\u00f6re ne kadar <strong>yenilik\u00e7i ve etkili<\/strong> olabilece\u011fini g\u00f6steriyor. \u00d6n\u00fcm\u00fczdeki y\u0131llarda, GLP\u20111 tabanl\u0131 peptitlerin, kombine agonistlerin ve hatta oral peptit formlar\u0131n\u0131n klinik prati\u011fi daha da d\u00f6n\u00fc\u015ft\u00fcrmesi bekleniyor.\n<\/p>\n<h2>Kaynaklar (DOI)<\/h2>\n<ul>\n<li>Marso SP ve ark. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. <em>N Engl J Med<\/em>. 2016;375:1834\u20131844. doi:10.1056\/NEJMoa1607141<\/li>\n<li>Wilding JPH ve ark. Once-Weekly Semaglutide in Adults with Overweight or Obesity. <em>N Engl J Med<\/em>. 2021;384:989\u20131002. doi:10.1056\/NEJMoa2032183<\/li>\n<li>Rubino D ve ark. Step 2 Trial: Semaglutide in Type 2 Diabetes and Obesity. <em>Nat Med<\/em>. 2021;27:1910\u20131919. doi:10.1038\/s41591-021-01398-3<\/li>\n<li>Ahr\u00e9n B. GLP-1 Receptor Agonists: Clinical Pharmacology and Therapeutic Use. <em>Diabet Obes Metab<\/em>. 2018;20(S1):34\u201346. doi:10.1111\/dom.13494<\/li>\n<li>Muller TD ve ark. Glucagon-like Peptide 1 (GLP-1) in Pharmacology and Drug Discovery. <em>Nat Rev Drug Discov<\/em>. 2021;20:757\u2013780. doi:10.1038\/s41573-021-00144-4<\/li>\n<\/ul>\n<h2>SSS: Semaglutid ve GLP\u20111 Resept\u00f6r Agonistleri Hakk\u0131nda En \u00c7ok Sorulan 5 Soru<\/h2>\n<h3>1. Semaglutid ile ne kadar kilo verilebilir?<\/h3>\n<p>\nKlinik \u00e7al\u0131\u015fmalarda, haftal\u0131k semaglutid enjeksiyonu ve ya\u015fam tarz\u0131 de\u011fi\u015fiklikleriyle birlikte <strong>v\u00fccut a\u011f\u0131rl\u0131\u011f\u0131n\u0131n ortalama %10\u201315\u2019i<\/strong> oran\u0131nda kilo kayb\u0131 bildirilmi\u015ftir. Bireysel sonu\u00e7lar, ba\u015flang\u0131\u00e7 kilosu, beslenme, hareket d\u00fczeyi ve tedaviye uyuma g\u00f6re de\u011fi\u015fir.\n<\/p>\n<h3>2. Semaglutid sadece diyabet hastalar\u0131 i\u00e7in mi?<\/h3>\n<p>\nHay\u0131r. Semaglutidin hem <strong>tip 2 diyabet<\/strong> hem de &lt;strongobezite<\/strong> i\u00e7in onayl\u0131 farkl\u0131 form\u00fclasyonlar\u0131 vard\u0131r. Ancak diyabeti olmayan, sadece \u201cbirka\u00e7 kilo vermek isteyen\u201d ki\u015filer i\u00e7in rastgele kullan\u0131m uygun de\u011fildir; endikasyon, <strong>beden kitle indeksi ve ek hastal\u0131klara<\/strong> g\u00f6re hekim taraf\u0131ndan de\u011ferlendirilmelidir.\n<\/p>\n<h3>3. Semaglutid b\u0131rak\u0131l\u0131nca kilo geri gelir mi?<\/h3>\n<p>\nBir\u00e7ok hastada, semaglutid kesildikten sonra <strong>i\u015ftah art\u0131\u015f\u0131 ve k\u0131smi kilo geri al\u0131m\u0131<\/strong> g\u00f6r\u00fclebilir. Bu nedenle tedavi boyunca kazan\u0131lan sa\u011fl\u0131kl\u0131 beslenme ve hareket al\u0131\u015fkanl\u0131klar\u0131n\u0131n <strong>kal\u0131c\u0131 hale getirilmesi<\/strong> \u00e7ok \u00f6nemlidir. \u0130la\u00e7, ya\u015fam tarz\u0131 de\u011fi\u015fikliklerinin yerine de\u011fil, yan\u0131na eklenmelidir.\n<\/p>\n<h3>4. Semaglutid ins\u00fclinin yerini tutar m\u0131?<\/h3>\n<p>\nSemaglutid, <strong>ins\u00fclin de\u011fildir<\/strong> ve tip 1 diyabet tedavisinde ins\u00fclinin yerini alamaz. Tip 2 diyabette ise baz\u0131 hastalarda ins\u00fclin ihtiyac\u0131n\u0131 azaltabilir veya geciktirebilir; ancak bu, hastal\u0131\u011f\u0131n evresi ve bireysel duruma g\u00f6re de\u011fi\u015fir. Karar mutlaka endokrinoloji uzman\u0131 ile birlikte verilmelidir.\n<\/p>\n<h3>5. Semaglutid kimler i\u00e7in uygun de\u011fildir?<\/h3>\n<p>\nMed\u00fcller tiroid kanseri veya MEN2 \u00f6yk\u00fcs\u00fc olanlarda, a\u011f\u0131r pankreatit ge\u00e7irmi\u015f ki\u015filerde ve gebelikte genellikle <strong>\u00f6nerilmez<\/strong>. Ayr\u0131ca ciddi mide\u2011ba\u011f\u0131rsak hastal\u0131\u011f\u0131 olanlarda dikkatle de\u011ferlendirilmelidir. Her durumda, semaglutid kullan\u0131m\u0131 \u00f6ncesinde ayr\u0131nt\u0131l\u0131 <strong>t\u0131bbi \u00f6yk\u00fc ve muayene<\/strong> \u015fartt\u0131r.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>GLP\u20111 resept\u00f6r agonisti semaglutid nedir, nas\u0131l \u00e7al\u0131\u015f\u0131r? Tip 2 diyabet tedavisi, obezite ve kilo kayb\u0131ndaki etkileri, mekanizmas\u0131 ve klinik \u00e7al\u0131\u015fma sonu\u00e7lar\u0131yla semaglutid hakk\u0131nda bilimsel, detayl\u0131 bir rehber.<\/p>\n","protected":false},"author":1,"featured_media":10340,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[91],"tags":[846,825,794,791,512,716],"class_list":["post-10339","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-enzimler-biyokimya","tag-glp-1-reseptor-agonisti","tag-kilo-verme","tag-obezite-tedavisi","tag-semaglutid","tag-tip-2-diyabet","tag-zayiflama-ignesi"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=\/wp\/v2\/posts\/10339","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=10339"}],"version-history":[{"count":2,"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=\/wp\/v2\/posts\/10339\/revisions"}],"predecessor-version":[{"id":10343,"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=\/wp\/v2\/posts\/10339\/revisions\/10343"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=\/wp\/v2\/media\/10340"}],"wp:attachment":[{"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=10339"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=10339"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ortaakarsu.net\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=10339"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}